Psychedelic drugs to treat mental health disorders has been around for decades, but in 2020 this area received the focus of investors with added relevance as the current pandemic develops into a global mental health crisis. However, there are social and legal barriers making the adoption of psychedelics a viable treatment option. Subscribe to Dealroom’s Health newsletter, for weekly insights on healthtech, biotech and wellness: Accelerating adoption…